2-Chloro-2′-deoxyadenosine in the treatment of Sjögren's syndrome-associated B cell lymphoproliferation

Arthritis and Rheumatism

Volumn 46, Issue 8, 2002, Pages 2248-2249

  Voulgarelis, Michalis ^a   Petroutsos, George ^a   Moutsopoulos, Haralampos M ^a   Skopouli, Fotini N ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b HAROKOPIO UNIVERSITY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; RHEUMATOID FACTOR;

ADULT; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; EXOCRINE CELL; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OUTPATIENT; PRIORITY JOURNAL; SJOEGREN SYNDROME; TH2 CELL; VASCULITIS;

ADULT; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CLADRIBINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA; MALE; MIDDLE AGED; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 0036673867     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10434     Document Type: Article

References (4)

1. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome
2. Malignant lymphoma in primary Sjögren's syndrome: A multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome
3. 2-Chlodeoxyadenosine: A newer purine analog active in the treatment of indolent lymphoid malignancies
4. A pilot study of 2-chloro-2′-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis